OSE Immunotherapeutics Seeks Partner For Lead Drug

 
• By Lucie Ellis-Taitt
  
Emerging Company Profile Regular column feature image Version 2
OSE Immunotherapeutics targets lead drug at NSCLC patients that don't benefit from PD-1s
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Start-Ups & SMEs

More from Business